Navigation Links
Palatin Technologies, Inc. Announces Presentation and Publication on Validation of Scale for Subjective Male Sexual Arousal
Date:6/15/2011

CRANBURY, N.J., June 15, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN), a biopharmaceutical company developing bremelanotide for sexual dysfunction indications, announced presentation and publication of a report on validation of a scale for subjective male sexual arousal.  The underlying study was supported by grants from Palatin.

Michael A. Perelman, Ph.D., of the New York Presbyterian Hospital and the Weill Medical College of Cornell University, presented the poster on June 13, 2011 at the 20th World Congress for Sexual Health in Glasgow, United Kingdom.  The paper, entitled "The Subjective Sexual Arousal Scale for Men (SSASM): Preliminary Development and Psychometric Validation of a Multidimensional Measure of Subjective Male Sexual Arousal," has been published in the online version of the Journal of Sexual Medicine and will appear in a forthcoming print issue. Stanley E. Althof, Ph.D., Executive Director of the Center for Marital and Sexual Health of South Florida and Emeritus Professor, Case Western Reserve University School of Medicine, and Raymond C. Rosen, Ph.D., of New England Research Institutes, are co-authors on the paper with Dr. Perelman.

The presentation and paper describe development and psychometric validation of a self-administered scale for assessing subjective male sexual arousal.  Based upon recommendations of the Food and Drug Administration guidance on patient-reported outcome instruments, important aspects of male sexual arousal were identified through qualitative research of U.S. men with erectile dysfunction and healthy controls.

The Subjective Sexual Arousal Scale for Men (SSASM) may be useful in drug development for treatment of erectile dysfunction.  The SSASM is the first validated research instrument with a focus on assessing subjective male sexual arousal in men with erectile dysfunction in a clinical trial setting.

Palatin supported the underlying research efforts as part of its commitment to developing novel drugs for treating sexual dysfunction, including both female sexual dysfunction and male erectile dysfunction.

About Bremelanotide

Palatin Technologies, Inc. is developing subcutaneously administered bremelanotide for the treatment of female sexual dysfunction and erectile dysfunction in patients non-responsive to current therapies.  An at-home Phase 2 clinical trial of subcutaneously administered bremelanotide for pre-menopausal women with female sexual dysfunction is scheduled to start in the current calendar quarter.

About Palatin Technologies, Inc.

Palatin Technologies, Inc. is a biopharmaceutical company focused on discovering and developing targeted, receptor-specific small molecule and peptide therapeutics.  Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential.  For additional information regarding Palatin, please visit Palatin Technologies' website at http://www.palatin.com.


'/>"/>
SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 Results
2. Palatin Technologies, Inc. Announces Results of Annual Stockholders Meeting
3. Palatin Technologies, Inc. to Present at the ROTH 23rd Annual OC Growth Stock Conference
4. Palatin Technologies, Inc. Announces Pricing of Public Offering of Common Stock and Warrants
5. Palatin Technologies, Inc. Announces Proposed Public Offering of Common Stock and Warrants
6. Palatin Technologies, Inc. December 31, 2010 Quarter Results; Teleconference and Webcast to be Held on February 24, 2011
7. Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2011 Results
8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2011 Results; Teleconference and Webcast to be held on November 16, 2010
9. Palatin Technologies, Inc. to Report Fiscal Year 2011 First Quarter Results; Teleconference and Webcast to be Held on November 16, 2010
10. Palatin Announces Strategic Realignment of Operations
11. Palatin Technologies, Inc. to Raise $2.0 Million Dollars in Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... (PRWEB) , ... December 02, ... ... (ETC), a consortium of pharmaceutical and biotechnology companies dedicated to collaboratively developing ... companies interested in supplying a vendor-supported, portable online UHPLC, with robust, probe-based ...
(Date:12/2/2016)... , December 2, 2016 The ... 2021, growing at a CAGR of 7.3% during the forecast period ... hospitals and diagnostic laboratories segment accounted for the largest share of ... ... report on global immunohistochemistry (IHC) market spread across 225 pages, profiling ...
(Date:11/30/2016)... 30, 2016  GenomOncology today announced the appointment of ... Affairs.  Dr. Coleman will oversee clinical content ... knowledge-enabled platform. The GenomOncology software suite empowers molecular pathologists with ... and clinical decision support, from quality control through reporting. ... , , ...
(Date:11/30/2016)... 2016 Biotest Pharmaceuticals Corporation (BPC), a leading ... the addition of its newest plasma collection center located ... . The 15,200 square foot state-of-the-art facility officially opened ... brings the total number of BPC,s plasma collection centers ... BPC,s Chief Executive Officer said "We are pleased to ...
Breaking Biology Technology:
(Date:11/24/2016)... -- Cercacor today introduced Ember TM Sport Premium ... measure hemoglobin, Oxygen Content, Oxygen Saturation, Perfusion Index, ... approximately 30 seconds. Smaller than a smartphone, using only ... key data about their bodies to help monitor these ... Hemoglobin carries oxygen to muscles. When hemoglobin and ...
(Date:11/19/2016)... Securus Technologies, a leading provider of civil ... corrections and monitoring, announced today that it has offered ... an independent technology judge determine who has the largest ... telephone calling platform, and the best customer service. ... of what we do – which clearly is not ...
(Date:11/15/2016)... ROCKVILLE, Md. , Nov. 15, 2016 /PRNewswire/ ... clinical company developing therapeutics focused on the gut ... public offering of 25,000,000 shares of its common ... its common stock at a price to the ... gross proceeds to Synthetic Biologics from the offering, ...
Breaking Biology News(10 mins):